Hill-Rom Holdings, Inc. (HRC) to Post FY2019 Earnings of $5.14 Per Share, Northcoast Research Forecasts

Hill-Rom Holdings, Inc. (NYSE:HRC) – Investment analysts at Northcoast Research increased their FY2019 EPS estimates for shares of Hill-Rom in a research report issued on Tuesday, November 6th. Northcoast Research analyst D. Keiser now anticipates that the medical technology company will earn $5.14 per share for the year, up from their prior estimate of $5.06. Northcoast Research currently has a “Buy” rating and a $104.00 price target on the stock. Northcoast Research also issued estimates for Hill-Rom’s Q4 2019 earnings at $1.70 EPS, Q4 2020 earnings at $1.90 EPS and FY2020 earnings at $5.77 EPS.

HRC has been the subject of several other reports. Barclays initiated coverage on shares of Hill-Rom in a research report on Monday, October 15th. They set an “equal weight” rating and a $95.00 target price for the company. ValuEngine upgraded shares of Hill-Rom from a “hold” rating to a “buy” rating in a research report on Tuesday. KeyCorp upped their price target on shares of Hill-Rom from $97.00 to $115.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 17th. Raymond James upped their price target on shares of Hill-Rom from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Monday. Finally, Morgan Stanley upped their price target on shares of Hill-Rom from $95.00 to $100.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 11th. Five analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $100.00.

Shares of NYSE HRC opened at $98.02 on Wednesday. The company has a debt-to-equity ratio of 1.11, a current ratio of 1.74 and a quick ratio of 1.30. The company has a market cap of $6.35 billion, a P/E ratio of 20.12, a price-to-earnings-growth ratio of 1.32 and a beta of 0.90. Hill-Rom has a 12-month low of $75.68 and a 12-month high of $98.96.

Hill-Rom (NYSE:HRC) last announced its earnings results on Friday, November 2nd. The medical technology company reported $1.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.51 by $0.12. The company had revenue of $759.20 million during the quarter, compared to analyst estimates of $750.90 million. Hill-Rom had a net margin of 8.86% and a return on equity of 21.10%. The firm’s quarterly revenue was up 2.8% compared to the same quarter last year. During the same period in the previous year, the business posted $1.32 earnings per share.

The company also recently declared a quarterly dividend, which will be paid on Monday, December 31st. Shareholders of record on Friday, December 14th will be given a $0.20 dividend. The ex-dividend date is Thursday, December 13th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.82%. Hill-Rom’s payout ratio is currently 16.84%.

Several institutional investors and hedge funds have recently bought and sold shares of the business. Marshall Wace LLP purchased a new position in shares of Hill-Rom in the second quarter worth $10,392,000. Millennium Management LLC lifted its holdings in shares of Hill-Rom by 32.3% in the second quarter. Millennium Management LLC now owns 583,635 shares of the medical technology company’s stock worth $50,975,000 after buying an additional 142,654 shares in the last quarter. Oakbrook Investments LLC lifted its holdings in shares of Hill-Rom by 34.5% in the third quarter. Oakbrook Investments LLC now owns 8,967 shares of the medical technology company’s stock worth $846,000 after buying an additional 2,300 shares in the last quarter. Verition Fund Management LLC purchased a new position in shares of Hill-Rom in the second quarter worth $1,081,000. Finally, State of Alaska Department of Revenue lifted its holdings in shares of Hill-Rom by 14.5% in the third quarter. State of Alaska Department of Revenue now owns 7,674 shares of the medical technology company’s stock worth $724,000 after buying an additional 974 shares in the last quarter. Institutional investors and hedge funds own 80.65% of the company’s stock.

About Hill-Rom

Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It provides medical surgical beds, intensive care unit beds, bariatric patient beds, lifts and other devices, non-invasive therapeutic products and surfaces, and communications technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.

Featured Article: How can you know how many shares are floating?

Earnings History and Estimates for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply